Capital DailyCapital Daily
Markets · Investing · Business
Capital DailyCapital Daily
Finance

Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus

VanEck's concentrated 26-stock portfolio has outpaced Fidelity's broader 334-holding fund over five years, but at a steeper cost and higher volatility.

Fidelity vs VanEck Healthcare ETFs: Broad Exposure or Pharma Focus

Published August 26, 2026 · Category: Finance

Overview

The Fidelity MSCI Health Care Index ETF (NYSEMKT:FHLC) provides broad, low-cost exposure to the entire healthcare sector, whereas the VanEck Pharmaceutical ETF (NASDAQ:PPH) offers a concentrated, higher-yielding focus on global pharmaceutical giants.

Investors choosing between these funds must decide between industry breadth and narrow specialization. Both funds serve as defensive anchors for an equity portfolio, but they differ significantly in their construction. The Fidelity fund captures the diverse breadth of the medical world, including equipment and services, while the VanEck fund drills specifically into the world's largest drug manufacturers. This comparison helps identify whether a broad sector tilt or a specific industry focus better fits a diversified portfolio.

Details

Beta measures price volatility relative to the S&P 500; beta is calculated from monthly returns over the available fund history (up to five years). The 1-yr return represents total return over the trailing 12 months. Dividend yield is the trailing-12-month distribution yield as of the close of trading on Aug. 20, 2026.

Continue reading

Source

Originally published at www.fool.com.

Related Articles

CD
Capital Daily Newsroom

Capital Daily covers markets, crypto and commodities for Asia & the Middle East — tier-1 desk research, AI-driven analysis, institutional-grade data. Tip our newsroom: [email protected]

Email the newsroom →
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Data may be delayed up to 15 minutes. Past performance is not indicative of future results. Consult a licensed financial advisor before making investment decisions.